Genitourinary Adverse Events During SGLT2 Inhibitor Therapy in Older Adults with Heart Failure: Frailty, Prevention, and Treatment Persistence—A Narrative Review
Journal of Gerontology and Geriatrics · 18.11.2026 · 74 (4) · 45
DOI: 10.3390/jgg74040045 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Gerontology and Geriatrics, online erschienen am 18.11.2026. Verfasst von Fulvio Cacciapuoti und 5 weiteren Autor:innen. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Patientensicherheit, Herzinsuffizienz, Gerontologische Pflege
Abstract (Originalsprache)
Sodium–glucose cotransporter-2 inhibitors (SGLT2i) improve outcomes across the heart failure (HF) spectrum, but genitourinary (GU) adverse events may complicate their use in older adults with frailty, multimorbidity, lower urinary tract dysfunction, and concomitant diuretic therapy. This review evaluates GU safety, prevention, and management during SGLT2i therapy in older adults with HF. A targeted narrative review of the literature was conducted using PubMed, supplemented by clinical guidelines, multidisciplinary consensus documents, and evidence syntheses, with the literature search updated through 20 September 2026. Priority was given to clinically relevant studies involving older adults with HF; evidence from broader populations was considered when direct evidence was unavailable. Genital mycotic infections are a consistent class-associated adverse event, whereas evidence regarding bacterial urinary tract infections (UTIs) remains mixed, and a consistent increase in severe UTI or urosepsis has not been established. In older adults with HF, frailty, urinary dysfunction, impaired mobility or cognition, and caregiver dependence may increase the clinical burden of GU symptoms and complicate their recognition and management. Osmotic diuresis, congestion, and concomitant loop-diuretic therapy may cause urinary symptoms that are mistaken for infection, contributing to unnecessary investigations or treatment. Evidence supporting non-antibiotic prophylaxis is predominantly indirect and does not justify routine preventive treatment. Most uncomplicated GU events can be managed without discontinuing SGLT2i therapy. A frailty-informed approach integrating symptom-driven assessment, antimicrobial stewardship, individualized volume management, and clinically appropriate temporary interruption and reinitiation may help preserve treatment persistence while maintaining patient safety. Further studies in frail older adults with HF are needed to define effective preventive and management strategies.
Zitieren
APA
Cacciapuoti, F., Caso, I., Nasti, R., Rocca, F. L., Cuomo, O., & Mauro, C. (2026). Genitourinary Adverse Events During SGLT2 Inhibitor Therapy in Older Adults with Heart Failure: Frailty, Prevention, and Treatment Persistence—A Narrative Review. Journal of Gerontology and Geriatrics, 74(4), 45. https://doi.org/10.3390/jgg74040045
Vancouver
Cacciapuoti F, Caso I, Nasti R, Rocca FL, Cuomo O, Mauro C. Genitourinary Adverse Events During SGLT2 Inhibitor Therapy in Older Adults with Heart Failure: Frailty, Prevention, and Treatment Persistence—A Narrative Review. Journal of Gerontology and Geriatrics. 2026;74(4):45. doi:10.3390/jgg74040045
BibTeX
@article{Cacciapuoti2026,
author = {Cacciapuoti, Fulvio and Caso, Ilaria and Nasti, Rodolfo and Rocca, Fulvio La and Cuomo, Osvaldo and Mauro, Ciro},
title = {Genitourinary Adverse Events During SGLT2 Inhibitor Therapy in Older Adults with Heart Failure: Frailty, Prevention, and Treatment Persistence—A Narrative Review},
journal = {Journal of Gerontology and Geriatrics},
year = {2026},
volume = {74},
number = {4},
pages = {45},
doi = {10.3390/jgg74040045}
}
EUVIMED